WO2008063837A9 - Dendritic cell tumor injection therapy and related vaccine - Google Patents
Dendritic cell tumor injection therapy and related vaccineInfo
- Publication number
- WO2008063837A9 WO2008063837A9 PCT/US2007/083161 US2007083161W WO2008063837A9 WO 2008063837 A9 WO2008063837 A9 WO 2008063837A9 US 2007083161 W US2007083161 W US 2007083161W WO 2008063837 A9 WO2008063837 A9 WO 2008063837A9
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- cells
- patient
- tumor
- activated
- adjuvant
- Prior art date
Links
- 238000002347 injection Methods 0.000 title claims description 43
- 239000007924 injection Substances 0.000 title claims description 43
- 229960005486 vaccine Drugs 0.000 title claims description 6
- 238000002560 therapeutic procedure Methods 0.000 title description 7
- 208000017815 Dendritic cell tumor Diseases 0.000 title description 2
- 206010028980 Neoplasm Diseases 0.000 claims abstract description 116
- 210000004443 dendritic cell Anatomy 0.000 claims abstract description 81
- 210000001744 T-lymphocyte Anatomy 0.000 claims abstract description 55
- 239000002671 adjuvant Substances 0.000 claims abstract description 44
- 238000002512 chemotherapy Methods 0.000 claims abstract description 41
- 238000000034 method Methods 0.000 claims abstract description 34
- 239000000427 antigen Substances 0.000 claims abstract description 22
- 108091007433 antigens Proteins 0.000 claims abstract description 22
- 102000036639 antigens Human genes 0.000 claims abstract description 22
- 210000001616 monocyte Anatomy 0.000 claims abstract description 22
- 210000004881 tumor cell Anatomy 0.000 claims abstract description 19
- 229940022399 cancer vaccine Drugs 0.000 claims abstract description 16
- 238000009566 cancer vaccine Methods 0.000 claims abstract description 16
- 238000011521 systemic chemotherapy Methods 0.000 claims abstract description 11
- 238000012258 culturing Methods 0.000 claims abstract description 4
- 210000001519 tissue Anatomy 0.000 claims description 32
- 210000004698 lymphocyte Anatomy 0.000 claims description 13
- 230000002601 intratumoral effect Effects 0.000 claims description 10
- 230000004913 activation Effects 0.000 claims description 8
- PGHMRUGBZOYCAA-UHFFFAOYSA-N ionomycin Natural products O1C(CC(O)C(C)C(O)C(C)C=CCC(C)CC(C)C(O)=CC(=O)C(C)CC(C)CC(CCC(O)=O)C)CCC1(C)C1OC(C)(C(C)O)CC1 PGHMRUGBZOYCAA-UHFFFAOYSA-N 0.000 claims description 7
- PGHMRUGBZOYCAA-ADZNBVRBSA-N ionomycin Chemical group O1[C@H](C[C@H](O)[C@H](C)[C@H](O)[C@H](C)/C=C/C[C@@H](C)C[C@@H](C)C(/O)=C/C(=O)[C@@H](C)C[C@@H](C)C[C@@H](CCC(O)=O)C)CC[C@@]1(C)[C@@H]1O[C@](C)([C@@H](C)O)CC1 PGHMRUGBZOYCAA-ADZNBVRBSA-N 0.000 claims description 7
- 239000011324 bead Substances 0.000 claims description 6
- 239000002555 ionophore Substances 0.000 claims description 6
- 230000000236 ionophoric effect Effects 0.000 claims description 6
- 108010045069 keyhole-limpet hemocyanin Proteins 0.000 claims description 6
- FYGDTMLNYKFZSV-URKRLVJHSA-N (2s,3r,4s,5s,6r)-2-[(2r,4r,5r,6s)-4,5-dihydroxy-2-(hydroxymethyl)-6-[(2r,4r,5r,6s)-4,5,6-trihydroxy-2-(hydroxymethyl)oxan-3-yl]oxyoxan-3-yl]oxy-6-(hydroxymethyl)oxane-3,4,5-triol Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1[C@@H](CO)O[C@@H](OC2[C@H](O[C@H](O)[C@H](O)[C@H]2O)CO)[C@H](O)[C@H]1O FYGDTMLNYKFZSV-URKRLVJHSA-N 0.000 claims description 5
- 229920002498 Beta-glucan Polymers 0.000 claims description 5
- 108010017213 Granulocyte-Macrophage Colony-Stimulating Factor Proteins 0.000 claims description 5
- 108090000978 Interleukin-4 Proteins 0.000 claims description 5
- 210000003563 lymphoid tissue Anatomy 0.000 claims description 5
- 230000009467 reduction Effects 0.000 claims description 5
- 102000004457 Granulocyte-Macrophage Colony-Stimulating Factor Human genes 0.000 claims 2
- 238000011282 treatment Methods 0.000 abstract description 33
- 210000004027 cell Anatomy 0.000 description 66
- 239000002609 medium Substances 0.000 description 17
- 230000004044 response Effects 0.000 description 15
- 201000011510 cancer Diseases 0.000 description 14
- 230000005855 radiation Effects 0.000 description 14
- 238000001959 radiotherapy Methods 0.000 description 12
- 206010061289 metastatic neoplasm Diseases 0.000 description 10
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 9
- 230000001394 metastastic effect Effects 0.000 description 9
- AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 description 8
- 238000002659 cell therapy Methods 0.000 description 8
- 230000028993 immune response Effects 0.000 description 8
- 108090000695 Cytokines Proteins 0.000 description 7
- 102000004127 Cytokines Human genes 0.000 description 7
- 230000003902 lesion Effects 0.000 description 7
- 210000003819 peripheral blood mononuclear cell Anatomy 0.000 description 7
- 206010067484 Adverse reaction Diseases 0.000 description 6
- 108010022366 Carcinoembryonic Antigen Proteins 0.000 description 6
- 102100025475 Carcinoembryonic antigen-related cell adhesion molecule 5 Human genes 0.000 description 6
- CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 description 6
- 230000006838 adverse reaction Effects 0.000 description 6
- 230000006907 apoptotic process Effects 0.000 description 6
- 210000004369 blood Anatomy 0.000 description 6
- 239000008280 blood Substances 0.000 description 6
- 239000002158 endotoxin Substances 0.000 description 6
- 210000002966 serum Anatomy 0.000 description 6
- 101001057504 Homo sapiens Interferon-stimulated gene 20 kDa protein Proteins 0.000 description 5
- 101001055144 Homo sapiens Interleukin-2 receptor subunit alpha Proteins 0.000 description 5
- 102100026878 Interleukin-2 receptor subunit alpha Human genes 0.000 description 5
- 208000009565 Pharyngeal Neoplasms Diseases 0.000 description 5
- 206010034811 Pharyngeal cancer Diseases 0.000 description 5
- 229960004397 cyclophosphamide Drugs 0.000 description 5
- 201000010099 disease Diseases 0.000 description 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 5
- 210000001165 lymph node Anatomy 0.000 description 5
- 230000035800 maturation Effects 0.000 description 5
- 210000005087 mononuclear cell Anatomy 0.000 description 5
- 208000037821 progressive disease Diseases 0.000 description 5
- 102100032937 CD40 ligand Human genes 0.000 description 4
- ZDZOTLJHXYCWBA-VCVYQWHSSA-N N-debenzoyl-N-(tert-butoxycarbonyl)-10-deacetyltaxol Chemical compound O([C@H]1[C@H]2[C@@](C([C@H](O)C3=C(C)[C@@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)C=4C=CC=CC=4)C[C@]1(O)C3(C)C)=O)(C)[C@@H](O)C[C@H]1OC[C@]12OC(=O)C)C(=O)C1=CC=CC=C1 ZDZOTLJHXYCWBA-VCVYQWHSSA-N 0.000 description 4
- 238000013459 approach Methods 0.000 description 4
- 238000004113 cell culture Methods 0.000 description 4
- 230000007423 decrease Effects 0.000 description 4
- 229960003668 docetaxel Drugs 0.000 description 4
- 238000002360 preparation method Methods 0.000 description 4
- 230000009885 systemic effect Effects 0.000 description 4
- 238000011277 treatment modality Methods 0.000 description 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- 102100035793 CD83 antigen Human genes 0.000 description 3
- GHASVSINZRGABV-UHFFFAOYSA-N Fluorouracil Chemical compound FC1=CNC(=O)NC1=O GHASVSINZRGABV-UHFFFAOYSA-N 0.000 description 3
- 102100039620 Granulocyte-macrophage colony-stimulating factor Human genes 0.000 description 3
- 102000006354 HLA-DR Antigens Human genes 0.000 description 3
- 108010058597 HLA-DR Antigens Proteins 0.000 description 3
- 101000946856 Homo sapiens CD83 antigen Proteins 0.000 description 3
- 206010067482 No adverse event Diseases 0.000 description 3
- 206010037660 Pyrexia Diseases 0.000 description 3
- 230000001464 adherent effect Effects 0.000 description 3
- 229940009456 adriamycin Drugs 0.000 description 3
- 210000000612 antigen-presenting cell Anatomy 0.000 description 3
- 238000009534 blood test Methods 0.000 description 3
- 238000013170 computed tomography imaging Methods 0.000 description 3
- 238000011443 conventional therapy Methods 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 229960002949 fluorouracil Drugs 0.000 description 3
- 238000007710 freezing Methods 0.000 description 3
- 230000008014 freezing Effects 0.000 description 3
- 238000003306 harvesting Methods 0.000 description 3
- 230000036039 immunity Effects 0.000 description 3
- 230000001506 immunosuppresive effect Effects 0.000 description 3
- 238000000338 in vitro Methods 0.000 description 3
- 230000006698 induction Effects 0.000 description 3
- 230000036210 malignancy Effects 0.000 description 3
- 239000003550 marker Substances 0.000 description 3
- 239000002243 precursor Substances 0.000 description 3
- 210000003289 regulatory T cell Anatomy 0.000 description 3
- 230000001988 toxicity Effects 0.000 description 3
- 231100000419 toxicity Toxicity 0.000 description 3
- OZFAFGSSMRRTDW-UHFFFAOYSA-N (2,4-dichlorophenyl) benzenesulfonate Chemical compound ClC1=CC(Cl)=CC=C1OS(=O)(=O)C1=CC=CC=C1 OZFAFGSSMRRTDW-UHFFFAOYSA-N 0.000 description 2
- 229920001817 Agar Polymers 0.000 description 2
- 102100036475 Alanine aminotransferase 1 Human genes 0.000 description 2
- 108010082126 Alanine transaminase Proteins 0.000 description 2
- 108010029697 CD40 Ligand Proteins 0.000 description 2
- 239000012591 Dulbecco’s Phosphate Buffered Saline Substances 0.000 description 2
- 208000000461 Esophageal Neoplasms Diseases 0.000 description 2
- 101000868215 Homo sapiens CD40 ligand Proteins 0.000 description 2
- 101000946889 Homo sapiens Monocyte differentiation antigen CD14 Proteins 0.000 description 2
- 206010061218 Inflammation Diseases 0.000 description 2
- 102000003855 L-lactate dehydrogenase Human genes 0.000 description 2
- 108700023483 L-lactate dehydrogenases Proteins 0.000 description 2
- 102100035877 Monocyte differentiation antigen CD14 Human genes 0.000 description 2
- 206010030155 Oesophageal carcinoma Diseases 0.000 description 2
- 208000005718 Stomach Neoplasms Diseases 0.000 description 2
- 239000008272 agar Substances 0.000 description 2
- 230000000259 anti-tumor effect Effects 0.000 description 2
- 230000030741 antigen processing and presentation Effects 0.000 description 2
- 230000000890 antigenic effect Effects 0.000 description 2
- 239000002246 antineoplastic agent Substances 0.000 description 2
- 230000001640 apoptogenic effect Effects 0.000 description 2
- 230000003190 augmentative effect Effects 0.000 description 2
- 238000002619 cancer immunotherapy Methods 0.000 description 2
- 230000001413 cellular effect Effects 0.000 description 2
- 238000012512 characterization method Methods 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
- 229960004316 cisplatin Drugs 0.000 description 2
- DQLATGHUWYMOKM-UHFFFAOYSA-L cisplatin Chemical compound N[Pt](N)(Cl)Cl DQLATGHUWYMOKM-UHFFFAOYSA-L 0.000 description 2
- 230000000139 costimulatory effect Effects 0.000 description 2
- DDRJAANPRJIHGJ-UHFFFAOYSA-N creatinine Chemical compound CN1CC(=O)NC1=N DDRJAANPRJIHGJ-UHFFFAOYSA-N 0.000 description 2
- 238000005138 cryopreservation Methods 0.000 description 2
- 229940127089 cytotoxic agent Drugs 0.000 description 2
- 201000004101 esophageal cancer Diseases 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- 238000000684 flow cytometry Methods 0.000 description 2
- 239000001963 growth medium Substances 0.000 description 2
- 230000003308 immunostimulating effect Effects 0.000 description 2
- 230000001024 immunotherapeutic effect Effects 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 238000011534 incubation Methods 0.000 description 2
- 230000004054 inflammatory process Effects 0.000 description 2
- 230000005012 migration Effects 0.000 description 2
- 238000013508 migration Methods 0.000 description 2
- 210000005259 peripheral blood Anatomy 0.000 description 2
- 239000011886 peripheral blood Substances 0.000 description 2
- 210000005105 peripheral blood lymphocyte Anatomy 0.000 description 2
- 230000003389 potentiating effect Effects 0.000 description 2
- 108090000765 processed proteins & peptides Proteins 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 230000001105 regulatory effect Effects 0.000 description 2
- 230000004043 responsiveness Effects 0.000 description 2
- 238000001228 spectrum Methods 0.000 description 2
- 238000011272 standard treatment Methods 0.000 description 2
- 238000013190 sterility testing Methods 0.000 description 2
- 206010001150 Adenocarcinoma gastric Diseases 0.000 description 1
- 102000002260 Alkaline Phosphatase Human genes 0.000 description 1
- 108020004774 Alkaline Phosphatase Proteins 0.000 description 1
- 108700028369 Alleles Proteins 0.000 description 1
- 102100024222 B-lymphocyte antigen CD19 Human genes 0.000 description 1
- 208000026310 Breast neoplasm Diseases 0.000 description 1
- 101150013553 CD40 gene Proteins 0.000 description 1
- 102000019034 Chemokines Human genes 0.000 description 1
- 108010012236 Chemokines Proteins 0.000 description 1
- 241000766026 Coregonus nasus Species 0.000 description 1
- 241000557626 Corvus corax Species 0.000 description 1
- 206010061819 Disease recurrence Diseases 0.000 description 1
- 241000588724 Escherichia coli Species 0.000 description 1
- 102000002812 Heat-Shock Proteins Human genes 0.000 description 1
- 108010004889 Heat-Shock Proteins Proteins 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 101000980825 Homo sapiens B-lymphocyte antigen CD19 Proteins 0.000 description 1
- 101000581981 Homo sapiens Neural cell adhesion molecule 1 Proteins 0.000 description 1
- 101000738771 Homo sapiens Receptor-type tyrosine-protein phosphatase C Proteins 0.000 description 1
- 101000914484 Homo sapiens T-lymphocyte activation antigen CD80 Proteins 0.000 description 1
- 206010057665 Injection site lymphadenopathy Diseases 0.000 description 1
- 206010022086 Injection site pain Diseases 0.000 description 1
- 206010053425 Injection site swelling Diseases 0.000 description 1
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 1
- 239000012480 LAL reagent Substances 0.000 description 1
- 241000239218 Limulus Species 0.000 description 1
- 208000008771 Lymphadenopathy Diseases 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 102100027347 Neural cell adhesion molecule 1 Human genes 0.000 description 1
- 208000002193 Pain Diseases 0.000 description 1
- 206010061902 Pancreatic neoplasm Diseases 0.000 description 1
- 239000004793 Polystyrene Substances 0.000 description 1
- 102100037422 Receptor-type tyrosine-protein phosphatase C Human genes 0.000 description 1
- 208000015634 Rectal Neoplasms Diseases 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 238000000692 Student's t-test Methods 0.000 description 1
- 108091008874 T cell receptors Proteins 0.000 description 1
- 230000005867 T cell response Effects 0.000 description 1
- 102000016266 T-Cell Antigen Receptors Human genes 0.000 description 1
- 102100027222 T-lymphocyte activation antigen CD80 Human genes 0.000 description 1
- 241000011102 Thera Species 0.000 description 1
- 238000008050 Total Bilirubin Reagent Methods 0.000 description 1
- 108090000340 Transaminases Proteins 0.000 description 1
- 102100040245 Tumor necrosis factor receptor superfamily member 5 Human genes 0.000 description 1
- PNNCWTXUWKENPE-UHFFFAOYSA-N [N].NC(N)=O Chemical compound [N].NC(N)=O PNNCWTXUWKENPE-UHFFFAOYSA-N 0.000 description 1
- 230000033289 adaptive immune response Effects 0.000 description 1
- 238000009098 adjuvant therapy Methods 0.000 description 1
- 208000037842 advanced-stage tumor Diseases 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- VREFGVBLTWBCJP-UHFFFAOYSA-N alprazolam Chemical compound C12=CC(Cl)=CC=C2N2C(C)=NN=C2CN=C1C1=CC=CC=C1 VREFGVBLTWBCJP-UHFFFAOYSA-N 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- 230000001093 anti-cancer Effects 0.000 description 1
- 230000005809 anti-tumor immunity Effects 0.000 description 1
- 230000006023 anti-tumor response Effects 0.000 description 1
- 238000011394 anticancer treatment Methods 0.000 description 1
- 230000010100 anticoagulation Effects 0.000 description 1
- 238000003149 assay kit Methods 0.000 description 1
- 230000006399 behavior Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 230000002146 bilateral effect Effects 0.000 description 1
- 238000001574 biopsy Methods 0.000 description 1
- 210000000481 breast Anatomy 0.000 description 1
- 239000013592 cell lysate Substances 0.000 description 1
- 239000002458 cell surface marker Substances 0.000 description 1
- 239000006285 cell suspension Substances 0.000 description 1
- 230000003833 cell viability Effects 0.000 description 1
- 230000007969 cellular immunity Effects 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 235000012000 cholesterol Nutrition 0.000 description 1
- 238000009535 clinical urine test Methods 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 208000029742 colonic neoplasm Diseases 0.000 description 1
- 238000002591 computed tomography Methods 0.000 description 1
- 238000011254 conventional chemotherapy Methods 0.000 description 1
- 230000002596 correlated effect Effects 0.000 description 1
- -1 counted Substances 0.000 description 1
- 229940109239 creatinine Drugs 0.000 description 1
- 210000004748 cultured cell Anatomy 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000008034 disappearance Effects 0.000 description 1
- BFMYDTVEBKDAKJ-UHFFFAOYSA-L disodium;(2',7'-dibromo-3',6'-dioxido-3-oxospiro[2-benzofuran-1,9'-xanthene]-4'-yl)mercury;hydrate Chemical compound O.[Na+].[Na+].O1C(=O)C2=CC=CC=C2C21C1=CC(Br)=C([O-])C([Hg])=C1OC1=C2C=C(Br)C([O-])=C1 BFMYDTVEBKDAKJ-UHFFFAOYSA-L 0.000 description 1
- 229960004679 doxorubicin Drugs 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 239000012636 effector Substances 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 108010072542 endotoxin binding proteins Proteins 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 238000001943 fluorescence-activated cell sorting Methods 0.000 description 1
- 238000013467 fragmentation Methods 0.000 description 1
- 238000006062 fragmentation reaction Methods 0.000 description 1
- 239000012595 freezing medium Substances 0.000 description 1
- 239000012737 fresh medium Substances 0.000 description 1
- 238000013110 gastrectomy Methods 0.000 description 1
- 206010017758 gastric cancer Diseases 0.000 description 1
- 229930195712 glutamate Natural products 0.000 description 1
- 201000010536 head and neck cancer Diseases 0.000 description 1
- 208000014829 head and neck neoplasm Diseases 0.000 description 1
- 208000006750 hematuria Diseases 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 238000002649 immunization Methods 0.000 description 1
- 230000003053 immunization Effects 0.000 description 1
- 230000005847 immunogenicity Effects 0.000 description 1
- 238000009169 immunotherapy Methods 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 239000000411 inducer Substances 0.000 description 1
- 230000036512 infertility Effects 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 230000005865 ionizing radiation Effects 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 238000002372 labelling Methods 0.000 description 1
- 210000000867 larynx Anatomy 0.000 description 1
- 238000011068 loading method Methods 0.000 description 1
- 230000008949 local secretion Effects 0.000 description 1
- 230000007787 long-term memory Effects 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 208000020816 lung neoplasm Diseases 0.000 description 1
- 208000018555 lymphatic system disease Diseases 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000000813 microbial effect Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000010172 mouse model Methods 0.000 description 1
- 238000011275 oncology therapy Methods 0.000 description 1
- 229940094443 oxytocics prostaglandins Drugs 0.000 description 1
- 238000007427 paired t-test Methods 0.000 description 1
- 210000000496 pancreas Anatomy 0.000 description 1
- 210000003800 pharynx Anatomy 0.000 description 1
- 238000007747 plating Methods 0.000 description 1
- 229920002223 polystyrene Polymers 0.000 description 1
- 238000002203 pretreatment Methods 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 230000000770 proinflammatory effect Effects 0.000 description 1
- 150000003180 prostaglandins Chemical class 0.000 description 1
- 201000001474 proteinuria Diseases 0.000 description 1
- 238000013094 purity test Methods 0.000 description 1
- 230000009257 reactivity Effects 0.000 description 1
- 210000000664 rectum Anatomy 0.000 description 1
- 230000000306 recurrent effect Effects 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 238000011255 standard chemotherapy Methods 0.000 description 1
- 210000000130 stem cell Anatomy 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 201000011549 stomach cancer Diseases 0.000 description 1
- 201000000498 stomach carcinoma Diseases 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 238000007910 systemic administration Methods 0.000 description 1
- 230000008685 targeting Effects 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 238000010257 thawing Methods 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 102000014898 transaminase activity proteins Human genes 0.000 description 1
- 208000030218 transient fever Diseases 0.000 description 1
- 230000032258 transport Effects 0.000 description 1
- 150000003626 triacylglycerols Chemical class 0.000 description 1
- 230000037455 tumor specific immune response Effects 0.000 description 1
- 230000035899 viability Effects 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0636—T lymphocytes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/461—Cellular immunotherapy characterised by the cell type used
- A61K39/4611—T-cells, e.g. tumor infiltrating lymphocytes [TIL], lymphokine-activated killer cells [LAK] or regulatory T cells [Treg]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/461—Cellular immunotherapy characterised by the cell type used
- A61K39/4615—Dendritic cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/462—Cellular immunotherapy characterized by the effect or the function of the cells
- A61K39/4622—Antigen presenting cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
- A61K39/4643—Vertebrate antigens
- A61K39/4644—Cancer antigens
- A61K39/46448—Cancer antigens from embryonic or fetal origin
- A61K39/464482—Carcinoembryonic antigen [CEA]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0639—Dendritic cells, e.g. Langherhans cells in the epidermis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K2035/124—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells the cells being hematopoietic, bone marrow derived or blood cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/515—Animal cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55516—Proteins; Peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55583—Polysaccharides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55588—Adjuvants of undefined constitution
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
- A61K2039/6031—Proteins
- A61K2039/6081—Albumin; Keyhole limpet haemocyanin [KLH]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
- A61K2239/31—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterized by the route of administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
- A61K2239/38—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the dose, timing or administration schedule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/20—Cytokines; Chemokines
- C12N2501/22—Colony stimulating factors (G-CSF, GM-CSF)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/20—Cytokines; Chemokines
- C12N2501/23—Interleukins [IL]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/50—Cell markers; Cell surface determinants
- C12N2501/515—CD3, T-cell receptor complex
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/999—Small molecules not provided for elsewhere
Definitions
- the present invention relates to treatment methods for cancer patients and, more particularly, to combinatorial treatment methods employing conventional cancer therapies with cancer immunotherapy. Description of the Prior Art
- DCs Dendritic cells
- Banchereau, J. et al, Ann NY Acad Sci, 987:180-7, 2003 These cells have the capacity to acquire antigenic material from their environment and to subsequently initiate vigorous immune responses. Recognizing this potential, DCs have been used as a platform to deliver candidate vaccines for cancer immunotherapy (den Brok, M.B. et al., Expert Rev Vaccines, 4:699-710, 2005).
- immature DCs are developed in vitro from monocytes or stem cell precursors, armed with the candidate vaccines in the form of tumor cell lysates, proteins or HLA class I allele specific peptides. The DCs are matured with selected cytokines and administered by intravenous or parenteral routes.
- Cyclophosphamide for example, has been recognized to not only exert immunostimulatory effects, but also to decrease the number of regulatory T cells and enhance apoptosis (Berd, D. et al., Cancer Res, 44:5439-43, 1984).
- the present invention meets this need by providing comprehensive combinatorial treatment methods for reducing the size of tumor cells in tumor tissue of a patient.
- a method for reducing the size of tumor cells in tumor tissue of a patient comprising collecting monocyte cells from a patient; culturing the monocyte cells with one or a plurality of factors to form immature dendritic cells from the monocyte cells; introducing the immature dendritic cells and an adjuvant into the tumor tissue of the patient; and introducing activated T cells into the tumor tissue of the patient.
- the activated T cells may be introduced several days following introducing the immature dendritic cells and the adjuvant in the patient, in order to generate antigen-specific T cells.
- the monocyte cells of the patient i.e., peripheral blood mononuclear cells (PBMCs)
- PBMCs peripheral blood mononuclear cells
- factors such as, for example, GM-CSF and IL-4.
- Activation of T cells may be effected by exposing T cells to anti-CD3 antibodies and an ionophore such as, for example, ionomycin.
- Activated lymphocyte medium may be prepared by using CD3-CD28 beads.
- Suitable adjuvants to be used in the methods of the present invention include, without limitation, activated lymphocyte medium (ALM), super lymphoid tissue extract, ⁇ -glucan or keyhole limpet hemocyanin.
- a method for reducing the size of tumor cells in tumor tissue of a patient further comprising pretreating a patient with local chemotherapy prior to introducing the immature dendritic cells, adjuvant and activated T cells into the tumor tissue of the patient.
- a method for reducing the size of tumor cells in tumor tissue of a patient further comprising pretreating a patient with systemic chemotherapy prior to introducing the immature dendritic cells, adjuvant and activated T cells into the tumor tissue of the patient.
- a method for reducing the size of tumor cells in tumor tissue of a patient further comprising pretreating a patient with systemic chemotherapy and local tumor irradiation prior to introducing the immature dendritic cells, adjuvant and activated T cells into the tumor tissue of the patient.
- a cancer vaccine precursor which when introduced into tumor tissue combines with an antigen for the reduction of the size of a tumor in a patient, in which the cancer vaccine comprises immature dendritic cells derived from monocytes collected from the patient, an adjuvant, antigens from the tumor in the patient, and activated T cells.
- the cancer vaccine comprises immature dendritic cells derived from monocytes collected from the patient, an adjuvant, antigens from the tumor in the patient, and activated T cells.
- Figure 1 provides four treatment protocols in accordance with embodiments of the invention
- Figure 2 shows PET CT imaging of recurrence of upper pharyngeal cancer in a 45 year old female (A) before, (B) about 3 weeks, (C) about 3.5 months, and (D) 9 months following AT cell treatment; and
- Figure 3 is a graph illustrating that CEA serum levels drop following treatment with dendritic cells and AT cells (Protocol IV).
- the present invention provides comprehensive combinatorial treatment methods that are safe and effective for reducing the size of tumor cells in tumor tissue of a patient.
- a method for reducing the size of tumor cells in tumor tissue of a patient comprising collecting monocyte cells from a patient; culturing the monocyte cells with one or a plurality of factors to form immature dendritic cells from the monocyte cells; introducing the immature dendritic cells and an adjuvant into the tumor tissue of the patient; and introducing activated T cells into the tumor tissue of the patient.
- the activated T cells may be introduced several days following introducing the immature dendritic cells and the adjuvant in the patient, in order to generate antigen-specific T cells.
- Introduction of the immature dendritic cells, adjuvant and activated T cells may be effected by intratumoral injection.
- the monocyte cells of the patient i.e., peripheral blood mononuclear cells (PBMCs)
- PBMCs peripheral blood mononuclear cells
- Activation of T cells may be effected by exposing T cells to anti-CD3 antibodies and an ionophore such as, for example, ionomycin.
- Activated lymphocyte medium may be prepared by using CD3-CD28 beads.
- Suitable adjuvants to be used in the methods of the present invention include, without limitation, activated lymphocyte medium, super lymphoid tissue extract, ⁇ -glucan or keyhole limpet hemocyanin.
- a method for reducing the size of tumor cells in tumor tissue of a patient further comprising pretreating a patient with local chemotherapy prior to introducing the immature dendritic cells, adjuvant and activated T cells into the tumor tissue of the patient.
- a method for reducing the size of tumor cells in tumor tissue of a patient further comprising pretreating a patient with systemic chemotherapy prior to introducing the immature dendritic cells, adjuvant and activated T cells into the tumor tissue of the patient.
- a method for reducing the size of tumor cells in tumor tissue of a patient further comprising pretreating a patient with systemic chemotherapy and local tumor irradiation prior to introducing the immature dendritic cells, adjuvant and activated T cells into the tumor tissue of the patient.
- a cancer vaccine precursor which when introduced into tumor tissue combines with an antigen for the reduction of the size of a tumor in a patient, in which the cancer vaccine comprises immature dendritic cells derived from monocytes collected from the patient, an adjuvant, antigens from the tumor in the patient, and activated T cells.
- patient is meant to refer to mammals, including humans.
- chemotherapeutic agents including cisplatin (CDDP), cyclophosphamide (Cytoxan), fluorouracil (5- FU), Docetaxel (DTX) or Adriamycin (ADM) used in conventional therapy for the specific malignancy, were given in order to induce apoptosis or reduce the presence of cells that might suppress the immune response.
- AT cell therapy was administered 3 days following immature DC and adjuvant treatment.
- Chemotherapy was administered intratumorally (Protocol III) or systemically (Protocol IV) or combined with radiation (Protocol V). Patients were followed for evidence of local and/or systemic adverse reactions. Tissue biopsies and blood tests were conducted 3-4 weeks following therapy. Local or metastatic tumor regression was evaluated by PET-CT imaging. If tumor regression was observed, treatment was repeated.
- PBMCs peripheral blood mononuclear cells
- MNCs mononuclear cells
- ACD-A ratio of 12:1, Baxter, Deerfield, IL
- the inlet rates were 40-60 ml/min with a collection rate of 1 ml/min and a separation factor of 700.
- MNCs were ficolled, cryopreserved at 1.5x10 8 cells/ml/vial in 10% DMSO in AIM-V medium (Gibco, Invitrogen, Tokyo), and stored at -80°C for 1-3 months. Prior to use in DC and AT cell culture, MNCs were thawed in a 3 V waterbath, washed twice in AIM-V medium, and counted.
- DC growth medium AIM-V medium supplemented with 800 IU/ml GM-CSF (CellGenix, Germany) + 500 U/ml IL4 (BD Pharmingen) was added to each of the flasks containing the adherent cells. Flasks were incubated at 37°C, 5% CO 2 . Growth media were refreshed on day 3 and DCs were harvested on day 7 by pipetting.
- Non-adherent T cells (approximately 6-9 xlO cells) collected following monocyte adherence for DC generation were washed and resuspended in 20 ml AIM-V medium. Five ml of this cell suspension and 35 ml of AT cell medium was added to each of four T-225cm 2 flasks coated with anti-CD3 antibody (Yamazaki, T. et al, Neurol Med Chir, Tokyo, 32:255-61, 1992). Flasks then were incubated for 7 days at 37°C, 5% CO 2 . Three hours prior to harvesting, 1 ug/ml ionomycin (Sigma, USA) was added to the medium to stimulate T cells (Sato, T.
- AT cell medium consisted of AIM-V medium supplemented with IL2 and autologous serum so that each flask contained a final level of 1000 IU/ml IL2 and 10% autologous serum.
- the anti-CD3 antibody-coating was prepared by adding 10 ml of 5 ug/ml anti-CD3 antibody (Orthoclone, OKT3 injection. Janssen Pharmaceutical, KK) in DPBS to flasks for 2h at room temperature followed by washing the flasks 3 times with 15 ml DPBS prior to adding cells. Harvested cells were cryopreserved and stored at -80°C prior to patient injection (0.5-3 months).
- a standard flow cytometry labeling protocol was used to determine cell surface marker expression (Parks, D. et al., Flow Cytometry and Fluorescence- Activated Cell Sorting; Raven Press Ltd, New York, 1989).
- DCs were characterized for surface marker expression after 7 days of culture and following thawing, prior to DC injection using fluorochrome-conjugated monoclonal antibodies against CDl Ic, CD14, CD40, CD80, CD83, CD86 and HLA-DR (BD Pharmingen).
- AT cells were evaluated for CD3, CD4, CD8, CDl Ic, CD14, CD19, CD25, CD45, CD56, CD154 (CD40L) and HLA-DR following culture.
- BD FACscan BD Biosciences
- Marker expression was presented as the mean level of fluorescence in patient cell cultures of the standard deviation.
- DCs and AT cell vials were thawed in a 37 0 C waterbath 1 hour prior to planned injection.
- One ml of AIM-V medium was added to each thawed vial; vials were allowed to sit for 2 minutes and then transferred to 50 ml of media and centrifuged (300xg, 7 min) to remove DMSO.
- Cells were resuspended in fresh media, counted, and a sample removed for sterility testing by agar plating. Remaining cells were distributed to two labeled microtubes (500 ul each) and placed on ice for delivery to the clinic for injection into patient's metastatic lesions. Cells were injected based on CT scan information.
- lymphocytes were suspended at 1 x 10 6 cells/ml in 50 ml XVIVO 10 medium (Cambrex, Walkersville, MD) per T-75 cm 2 flask and CD3-CD28 T cell expander beads (Dynal. Norway) (Levine, B.L. et al., J Immunol, 159:5921-30, 1997) were added at 1 cell to 1 bead ratio and incubated at 37°C, 5% CO 2 for 2 days. The supematants were harvested by centrifugation at 300xg for 7 min and stored at 4°C for later use. All adjuvants were delivered intratumorally at the same time as delivery of DCs.
- the type of chemotherapy was selected based on standard treatment for the particular cancer. Chemotherapy was administered intratumorally or systemically depending on the protocol. Twenty-one patients received Cyclophosphamide (CPM, 5-800 mg, Shinogi), five patients received Cisplatin (CDDP, 2.5-5.0 mg, Nihon Kayaku), one patient received Docetaxel (DTX, 55mg, Aventis), and one patient received Doxorubicin (ADM, 20mg, Kyowa Hakko). CDDP was administered systemically in combination with Fluorouracil (5-FU, 900 mg/day, Kyowa Hakko) in one patient with upper pharyngeal cancer.
- CPM Cyclophosphamide
- CDDP Cisplatin
- DTX Docetaxel
- ADM Doxorubicin
- CDDP was administered systemically in combination with Fluorouracil (5-FU, 900 mg/day, Kyowa Hakko) in one patient with upper pharyngeal cancer.
- Radiotherapy (20-50 Gy) was given to the two patients on Protocol V.
- Radiotherapy was delivered to patients according to a defined protocol (Shimamura, H. et al., Eur Surg Res, 37:228-34, 2005).
- the radiation area of the tumor site was designated in advance and radiation was given at 2-2.5 Gy doses during a 3-4 week period. Radiotherapy was performed during the same period as chemotherapy.
- DCs were injected intratumorally seven days following the completion of radiotherapy and AT cells were injected intratumorally ten days following completion of radiotherapy or three days following DC injection in the applicable protocols.
- Carcinoembryonic antigen (CEA) levels elevated in cancer were used to monitor patient responses to treatment and disease recurrence. Tumor size of the injected and irradiated sites, as well as metastatic sites, was evaluated prior to and 3-4 weeks following treatment using PET-CT imaging and Response Evaluation Criteria in Solid Tumors (RECIST). Baseline sums were assessed as the largest diameter in measurable lesions.
- CR complete response
- PR partial response
- SD stable disease
- PD progressive disease
- Adherent PBMCs can be differentiated to DCs. Seven day cultured adherent cells from patients with a variety of cancers expressed costimulatory markers and low CD83 surface antigen, indicative of immature DCs (Table 3). Cell viability remained high at 85-95% following 7 days in culture, as well as following cryopreservation. Lymphocytes treated with anti-CD3 and ionomycin for activated T cell therapy expressed CD25 and CD4OL (Table 3). The viability of the stimulated cells ranged from 75-90% prior to and following cryopreservation.
- GAT glutamate oxaloacetic transaminase
- GPT glutamic pyruvic transaminase
- LDH lactate dehydrogenase
- BUN blood urea nitrogen
- creatinine total cholesterol, triglycerides, blood sugar, hematuria or proteinuria.
- CR Complete Response
- PR Partial Response
- SD Stable Disease
- PD Progressive Disease
- chemo tumor tumor injection of chemotherapy
- chemo sys systemic administration of chemotherapy
- rad tumor irradiation
- PET-CT data showed improvement in both DC-injected and metastatic sites
- Serum CEA levels showed a steady decline reaching a level of 6.7 at the latest examination.
- Progressive disease was observed in four patients receiving DCs alone or DCs with chemotherapy (Protocols I and II) and in one patient receiving DCs and AT cells with chemotherapy and radiation (Protocol V). In the latter, stable disease was observed for 1 month with progression at 3 months in untreated tumors. IV. Discussion
- Anti-cancer treatments including, tumor irradiation, chemotherapy and adoptive cellular therapy have shown effectiveness on their own.
- This study showed that combining the unique properties of the different treatment modalities within single protocols significantly augmented anti-tumor responses.
- DCs serve as important antigen presenting cells for the induction of specific T cell immunity (Banchereau, J.
- Ionizing radiation and chemotherapy is used to induce apoptosis.
- Tumor irradiation typically produces inflammation due to release of intracellular contents into the surrounding environment accompanied by, but not limited to, activation of cytokines, prostaglandins and heat shock proteins.
- Local delivery of chemotherapy creates a similar environment at the tumor site.
- Such strategies produce a milieu that facilitates antigen acquisition, processing, and maturation, as well as stimulate migration of DCs to draining lymph nodes where they interact with a broad range of potential effector cells.
- tumor cells undergoing apoptosis may not induce immunity due to local secretion of immunosuppressive factors such as TGFO and ILlO and the lack of enough systemic functional DCs to reach the peritumoral region (Bodey, B. et al., Anticancer Res., 20: 2665-76, 2000).
- the tumor environment determines the state of maturation which can result in the induction of tolerance or immunity. Therefore, to complete DC activation at the injected site, other proinflammatory cytokines or immune-provoking substances may need to be combined with the immature DCs.
- DCs activate T cells and their interaction is important for the establishment of an effective immune response.
- Activated T cells could influence antigen presentation by DCs by a number of mechanisms.
- AT cells express surface molecules that physically interact with immature DCs and in addition produce cytokines and chemokines that influence the maturation and migration of DCs to regional lymph nodes where adaptive immune responses to acquired antigens are generated. As a consequence, a tumor specific immune response potentially is developed and long-term memory established.
- T cells have been expanded by a variety of methods including in vitro stimulation to elicit antigen-specific T cells from peripheral blood using cells engineered for antigen presentation (e.g., DCs pulsed with peptide or RNA transfected) or artificial antigen presenting cells.
- in vitro stimulation to elicit antigen-specific T cells from peripheral blood using cells engineered for antigen presentation (e.g., DCs pulsed with peptide or RNA transfected) or artificial antigen presenting cells.
- Harvesting infiltrating lymphocytes from tumor cells yield polyclonal T cell populations with broad reactivity to tumor. Re-infusing these cells after in vitro expansion has been used as an immunotherapeutic treatment modality.
- AT cells were expanded from peripheral blood lymphocytes by anti-CD3-IL2 culture and ionomycin activation to upregulate CD4OL.
- Cultured AT cells were injected intratumorally, several days following DC injection, with the idea that antigen-specific T cells could be generated.
- Patients receiving AT cell therapy were pretreated with: I) local chemotherapy (Protocol III), 2) systemic chemotherapy (Protocol IV), or 3) systemic chemotherapy and local tumor irradiation (Protocol V).
- Chemotherapeutic agents were administered systemically or locally in an attempt to determine if these agents could be used safely and effectively with immunotherapeutic procedures.
- the doses of chemotherapy were not the amount generally considered optimal for treating the patients' malignancy but rather as support for developing an immune response to the cancer.
- Chemotherapy may induce apoptosis in the tumor cell augmenting antigen uptake. More importantly, these drugs may effect regulatory T cells. Regulatory cells generally defined as CD4 + CD25 + have been found in most human solid tumors at elevated numbers with frequencies likely correlated to overall survival (Beyer, M. et al., Blood 108: 804-11, 2006). Their elimination by direct targeting of CD25 on the cell surface or preferential destruction is known to result in the generation of tumor-specific and enhanced responses to immunotherapy.
Abstract
The present invention provides effective, safe, comprehensive combinatorial treatment methods that are safe and effective for reducing the size of tumor cells in tumor tissue of a patient. The methods include reducing the size of tumor cells in tumor tissue of a patient by collecting monocyte cells from a patient; culturing the monocyte cells with one or a plurality of factors to form immature dendritic cells from the monocyte cells; introducing the immature dendritic cells and an adjuvant into the tumor tissue of the patient; and introducing activated T cells into the tumor tissue of the patient. The methods further comprise pretreating a patient with local chemotherapy, systemic chemotherapy, tumor irradiation or systemic chemotherapy in combination with local tumor irradiation prior to introducing the immature dendritic cells, adjuvant and activated T cells into the tumor tissue of the patient. Also provided is a cancer vaccine for reducing the size of a tumor in a patient, comprised of immature dendritic cells derived from monocytes collected from the patient, an adjuvant, tumor antigens from the patient, and activated T cells.
Description
DENDRITIC CELL TUMOR INJECTION THERAPY AND RELATED
VACCINE
CROSS REFERENCE TO RELATED APPLICATIONS
[0001] The present application claims priority to United States Provisional Application Number 60/855,905, filed October 31, 2006, which is incorporated herein by reference.
BACKGROUND OF THE INVENTION Field of the Invention
[0002] The present invention relates to treatment methods for cancer patients and, more particularly, to combinatorial treatment methods employing conventional cancer therapies with cancer immunotherapy. Description of the Prior Art
[0003] Dendritic cells (DCs) are the sentinel antigen presenting cells of the immune system (Banchereau, J. et al, Ann NY Acad Sci, 987:180-7, 2003). These cells have the capacity to acquire antigenic material from their environment and to subsequently initiate vigorous immune responses. Recognizing this potential, DCs have been used as a platform to deliver candidate vaccines for cancer immunotherapy (den Brok, M.B. et al., Expert Rev Vaccines, 4:699-710, 2005). In the majority of these studies, immature DCs are developed in vitro from monocytes or stem cell precursors, armed with the candidate vaccines in the form of tumor cell lysates, proteins or HLA class I allele specific peptides. The DCs are matured with selected cytokines and administered by intravenous or parenteral routes.
[0004] As an alternative approach, injection of immature DCs with adjuvant directly into a patient's tumor tissue theoretically allows these cells to acquire a variety of products of the tumor cell at the injection site capable of enhancing the generation of an immune response to a broad array of antigenic determinants (Chi, K.H. et al., J Immunother, 28:129-35, 2005).
[0005] Combining intratumoral injection of immature DCs with conventional treatments, such as radiotherapy and chemotherapy, has been suggested to augment immune responses and improve clinical outcome (Hoffmann T.K. et al., Cancer Res, 60:3542-9, 2000). Such treatments can induce apoptosis and create a milieu which enhances the ability of DCs to take up tumor antigens, mature and migrate to regional
lymph nodes where they efficiently present the tumor antigens to T cells (Pierre, P. et al., Nature, 388:787-92, 1997). Administration of chemotherapy to control immunosuppressive regulatory T cells or injection with other cellular products, such as activated T (AT) cells, also has been suggested to help enhance immune responsiveness (Berd, D. et al., Cancer Res, 44:5439-43, 1984). Cyclophosphamide, for example, has been recognized to not only exert immunostimulatory effects, but also to decrease the number of regulatory T cells and enhance apoptosis (Berd, D. et al., Cancer Res, 44:5439-43, 1984). Infusions of autologous AT cells, which express CD4OL and are potent inducers of DC maturation, have been clinically shown to be well-tolerated. Infused cells are able to significantly expand in vivo and maintain a broad T cell spectrum (Berger C. et al., Blood, 101 : 476-84, 2003). The administration of large numbers of AT cells, therefore, has the potential to increase the pool of T cells capable of reacting against tumors. Moreover, the release of cytokines, such as IFNγ by T cells, may further enhance antitumor effects. [0006] There exists a need, however, to provide a more effective treatment protocol for patients with cancer.
SUMMARY OF THE INVENTION
[0007] The present invention meets this need by providing comprehensive combinatorial treatment methods for reducing the size of tumor cells in tumor tissue of a patient.
[0008] In an aspect of the present invention, a method is provided for reducing the size of tumor cells in tumor tissue of a patient, comprising collecting monocyte cells from a patient; culturing the monocyte cells with one or a plurality of factors to form immature dendritic cells from the monocyte cells; introducing the immature dendritic cells and an adjuvant into the tumor tissue of the patient; and introducing activated T cells into the tumor tissue of the patient. The activated T cells may be introduced several days following introducing the immature dendritic cells and the adjuvant in the patient, in order to generate antigen-specific T cells.
[0009] Introduction of the immature dendritic cells, adjuvant and activated T cells may be effected by intratumoral injection.
[0010] The monocyte cells of the patient, i.e., peripheral blood mononuclear cells (PBMCs), may be cultured with factors such as, for example, GM-CSF and IL-4.
[0011] Activation of T cells may be effected by exposing T cells to anti-CD3 antibodies and an ionophore such as, for example, ionomycin. [0012] Activated lymphocyte medium may be prepared by using CD3-CD28 beads. [0013] Suitable adjuvants to be used in the methods of the present invention include, without limitation, activated lymphocyte medium (ALM), super lymphoid tissue extract, β-glucan or keyhole limpet hemocyanin.
[0014] In another aspect of the present invention, there is provided a method for reducing the size of tumor cells in tumor tissue of a patient, further comprising pretreating a patient with local chemotherapy prior to introducing the immature dendritic cells, adjuvant and activated T cells into the tumor tissue of the patient. [0015] In another aspect of the present invention, there is provided a method for reducing the size of tumor cells in tumor tissue of a patient, further comprising pretreating a patient with systemic chemotherapy prior to introducing the immature dendritic cells, adjuvant and activated T cells into the tumor tissue of the patient. [0016] In another aspect of the present invention, there is provided a method for reducing the size of tumor cells in tumor tissue of a patient, further comprising pretreating a patient with systemic chemotherapy and local tumor irradiation prior to introducing the immature dendritic cells, adjuvant and activated T cells into the tumor tissue of the patient.
[0017] In another aspect of the present invention, there is provided a cancer vaccine precursor which when introduced into tumor tissue combines with an antigen for the reduction of the size of a tumor in a patient, in which the cancer vaccine comprises immature dendritic cells derived from monocytes collected from the patient, an adjuvant, antigens from the tumor in the patient, and activated T cells. [0018] It is an object of the present invention to provide a more safe, effective combinatorial treatment protocol for patients with cancer.
[0019] It is another object of the present invention to provide an effective, safe method for reducing the size of tumor cells in a patient using conventional therapy(s) plus intratumoral injection of immature dendritic cells, an adjuvant and activated T cells.
[0020] It is another object of the present invention to provide an effective, safe cancer vaccine for reducing the size of a tumor in a patient, in which the cancer vaccine comprises immature dendritic cells, an adjuvant and activated T cells.
BRIEF DESCRIPTION OF THE DRAWINGS
[0021] A full understanding of the invention can be gained from the following description of the preferred embodiments when read in conjunction with the accompanying drawings in which:
[0022] Figure 1 provides four treatment protocols in accordance with embodiments of the invention;
[0023] Figure 2 shows PET CT imaging of recurrence of upper pharyngeal cancer in a 45 year old female (A) before, (B) about 3 weeks, (C) about 3.5 months, and (D) 9 months following AT cell treatment; and
[0024] Figure 3 is a graph illustrating that CEA serum levels drop following treatment with dendritic cells and AT cells (Protocol IV).
DESCRIPTION OF THE PREFERRED EMBODIMENTS
[0025] The present invention provides comprehensive combinatorial treatment methods that are safe and effective for reducing the size of tumor cells in tumor tissue of a patient.
[0026] In an embodiment of the present invention, there is provided a method for reducing the size of tumor cells in tumor tissue of a patient, comprising collecting monocyte cells from a patient; culturing the monocyte cells with one or a plurality of factors to form immature dendritic cells from the monocyte cells; introducing the immature dendritic cells and an adjuvant into the tumor tissue of the patient; and introducing activated T cells into the tumor tissue of the patient. The activated T cells may be introduced several days following introducing the immature dendritic cells and the adjuvant in the patient, in order to generate antigen-specific T cells. [0027] Introduction of the immature dendritic cells, adjuvant and activated T cells may be effected by intratumoral injection.
[0028] The monocyte cells of the patient, i.e., peripheral blood mononuclear cells (PBMCs), may be cultured with factors such as, for example, GM-CSF and IL-4. [0029] Activation of T cells may be effected by exposing T cells to anti-CD3 antibodies and an ionophore such as, for example, ionomycin. [0030] Activated lymphocyte medium may be prepared by using CD3-CD28 beads.
[0031] Suitable adjuvants to be used in the methods of the present invention include, without limitation, activated lymphocyte medium, super lymphoid tissue extract, β-glucan or keyhole limpet hemocyanin.
[0032] In another embodiment of the present invention, there is provided a method for reducing the size of tumor cells in tumor tissue of a patient, further comprising pretreating a patient with local chemotherapy prior to introducing the immature dendritic cells, adjuvant and activated T cells into the tumor tissue of the patient. [0033] In another embodiment of the present invention, there is provided a method for reducing the size of tumor cells in tumor tissue of a patient, further comprising pretreating a patient with systemic chemotherapy prior to introducing the immature dendritic cells, adjuvant and activated T cells into the tumor tissue of the patient. [0034] In another embodiment of the present invention, there is provided a method for reducing the size of tumor cells in tumor tissue of a patient, further comprising pretreating a patient with systemic chemotherapy and local tumor irradiation prior to introducing the immature dendritic cells, adjuvant and activated T cells into the tumor tissue of the patient.
[0035] In another embodiment of the present invention, there is provided a cancer vaccine precursor which when introduced into tumor tissue combines with an antigen for the reduction of the size of a tumor in a patient, in which the cancer vaccine comprises immature dendritic cells derived from monocytes collected from the patient, an adjuvant, antigens from the tumor in the patient, and activated T cells. [0036] As used herein, "patient" is meant to refer to mammals, including humans. [0037] The present invention is more particularly described in the following non- limiting example, which is intended to be illustrative only, as numerous modifications and variations therein will be apparent to those skilled in the art.
EXAMPLE I. Introduction
[0038] A pilot safety trial was conducted to investigate whether combining conventional treatment with DC and AT cell therapy would be well-tolerated. Several protocols were developed, in which immature DCs and AT cells were prepared from peripheral blood and injected into metastatic lesions in patients with advanced stages of malignancies. Patients first were injected with autologous immature DCs and adjuvant on day 0. Once it was established that the immature DC injection did not
induce adverse reactions, additional treatment modalities known to augment immune responses without substantial toxicity were incorporated into different treatment arms. Radiotherapy or chemotherapy was given prior to immature DC administration. Specific tumor areas were subjected to radiotherapy (20-50Gy) to elicit antigenicity resulting from fragmentation of tumor DNA. In some cases, chemotherapeutic agents, including cisplatin (CDDP), cyclophosphamide (Cytoxan), fluorouracil (5- FU), Docetaxel (DTX) or Adriamycin (ADM) used in conventional therapy for the specific malignancy, were given in order to induce apoptosis or reduce the presence of cells that might suppress the immune response. AT cell therapy was administered 3 days following immature DC and adjuvant treatment. II. Patients and methods
1. Patient treatment
[0039] Thirty-seven patients aged 41-83 years old were enrolled in the DC and AT cell therapy study protocols. All patients had relapsed after receiving and failing standard chemotherapy and/or radiation indicated for their cancer. The types of cancer and number of cases included in the study are listed in Table 1. Patients were placed in study protocols, summarized in Table 2.
Table 1 Clinical Cases Treated with DC-based Thera
Table 2
Summary of Study Protocols DC intratumoral injection with adjuvant plus:
Protocol No.
(No. cases) Chemotherapy
Local tumor Systemic Radiation AT cells
[0040] All patients received immature DCs (ranging from 4.9 x 106 to 5.9x109 per injection) and an adjuvant, either alone or combined with conventional chemotherapy, radiation and/or AT cells (4.IxIO1 to 7.5xlO8). Prior to treatment, tumors were biopsied and blood tests performed. Figure 1 illustrates the course of treatment in each of five protocols developed successively. All patients were given immature DCs and adjuvant on day 0. Patients enrolled in Protocol I received immature DCs and adjuvant. Protocol II patients were pretreated with local chemotherapy prior to receiving immature DCs and adjuvant. In other groups of patients, AT cells also were given at three days following immature DC and adjuvant injection with or without pre-treatment with chemotherapy or radiation. Chemotherapy was administered intratumorally (Protocol III) or systemically (Protocol IV) or combined with radiation (Protocol V). Patients were followed for evidence of local and/or systemic adverse reactions. Tissue biopsies and blood tests were conducted 3-4 weeks following therapy. Local or metastatic tumor regression was evaluated by PET-CT imaging. If tumor regression was observed, treatment was repeated.
2. Collection and isolation of peripheral blood mononuclear cells (PBMCs)
[0041] Leukaphereses were performed on a COBE Spectra blood separator (Gambro KK, Tokyo, Japan) using the program for collection of mononuclear cells (MNCs) (version 7.1) with manual adjustments of the plasma pump. Anticoagulation was achieved with ACD-A (ratio of 12:1, Baxter, Deerfield, IL). The inlet rates were 40-60 ml/min with a collection rate of 1 ml/min and a separation factor of 700. MNCs were ficolled, cryopreserved at 1.5x108 cells/ml/vial in 10% DMSO in AIM-V medium (Gibco, Invitrogen, Tokyo), and stored at -80°C for 1-3 months. Prior to use in DC and AT cell culture, MNCs were thawed in a 3 V waterbath, washed twice in AIM-V medium, and counted.
3. Generation of immature DCs (iDCs)
[0042] Thawed MNCs (approximately 6x108) were resuspended in 20 ml AIM-V medium and distributed in 5 ml aliquots to 4-T-75cm2 polystyrene flasks each
containing 1 Oral of AIM-V medium. Following a 2h incubation at 37°C, nonadherent cells were removed by pipette, transferred to conical tubes and reserved for AT cell preparation (see below). Fifteen ml of DC growth medium (AIM-V medium supplemented with 800 IU/ml GM-CSF (CellGenix, Germany) + 500 U/ml IL4 (BD Pharmingen) was added to each of the flasks containing the adherent cells. Flasks were incubated at 37°C, 5% CO2. Growth media were refreshed on day 3 and DCs were harvested on day 7 by pipetting. Harvested cells were counted and resuspended in AIM-V freezing medium containing 20% autologous serum + 10% DMSO, then cryopreserved in BICELL containers (Nihon Freezer Co., Tokyo, Japan), which allows for gradual freezing of cells similar to that of programmed freezing (1°C per minute freezing rate). Cells were stored at -80°C until patient injection (0.5-3 months).
4. Preparation of AT cells
[0043] Non-adherent T cells (approximately 6-9 xlO cells) collected following monocyte adherence for DC generation were washed and resuspended in 20 ml AIM-V medium. Five ml of this cell suspension and 35 ml of AT cell medium was added to each of four T-225cm2 flasks coated with anti-CD3 antibody (Yamazaki, T. et al, Neurol Med Chir, Tokyo, 32:255-61, 1992). Flasks then were incubated for 7 days at 37°C, 5% CO2. Three hours prior to harvesting, 1 ug/ml ionomycin (Sigma, USA) was added to the medium to stimulate T cells (Sato, T. et al., Cancer Immunol Immunother, 53:53-61, 2004). AT cell medium consisted of AIM-V medium supplemented with IL2 and autologous serum so that each flask contained a final level of 1000 IU/ml IL2 and 10% autologous serum. The anti-CD3 antibody-coating was prepared by adding 10 ml of 5 ug/ml anti-CD3 antibody (Orthoclone, OKT3 injection. Janssen Pharmaceutical, KK) in DPBS to flasks for 2h at room temperature followed by washing the flasks 3 times with 15 ml DPBS prior to adding cells. Harvested cells were cryopreserved and stored at -80°C prior to patient injection (0.5-3 months).
5. Sterility and purity testing of cell cultures
[0044] Seven days prior to harvesting cells, microbial testing was started by incubation of cultured cells on agar at 370C. Only negatively tested cultures were used clinically. Cell purity was assessed by determination of endotoxin levels (<0.5 EU/ml) using a commercially available chromogenic endotoxin assay kit according to the manufacturer's instruction (Toxicolor system LS-50M, Seikagaku
Corp., Tokyo, Japan). The concentration of endotoxin in each sample was measured with Limulus amoebocyte lysate (LAL). Briefly, 50 ul of each sample was transferred to an endotoxin-free 96-well plate (Toxipet LP; Seikagaku), and then 50 ul of the LAL reagent was added to each well, mixed and incubated at 37°C for 30 min. To stop the reaction, 0.8 M acetic acid was added to each well, mixed and measured at 405 run. Endotoxin levels were calculated against a reference endotoxin, E. coli 011 1:B4 LPS (Toxicolor system CSE; Seikagaku).
6. Characterization of cell cultures
[0045] A standard flow cytometry labeling protocol was used to determine cell surface marker expression (Parks, D. et al., Flow Cytometry and Fluorescence- Activated Cell Sorting; Raven Press Ltd, New York, 1989). DCs were characterized for surface marker expression after 7 days of culture and following thawing, prior to DC injection using fluorochrome-conjugated monoclonal antibodies against CDl Ic, CD14, CD40, CD80, CD83, CD86 and HLA-DR (BD Pharmingen). AT cells were evaluated for CD3, CD4, CD8, CDl Ic, CD14, CD19, CD25, CD45, CD56, CD154 (CD40L) and HLA-DR following culture. Minimally, 10,000 events were acquired on a BD FACscan (BD Biosciences) and data were analyzed using Cell Quest analysis software. Marker expression was presented as the mean level of fluorescence in patient cell cultures of the standard deviation.
7. Preparation of cells for injection
[0046] DCs and AT cell vials were thawed in a 370C waterbath 1 hour prior to planned injection. One ml of AIM-V medium was added to each thawed vial; vials were allowed to sit for 2 minutes and then transferred to 50 ml of media and centrifuged (300xg, 7 min) to remove DMSO. Cells were resuspended in fresh media, counted, and a sample removed for sterility testing by agar plating. Remaining cells were distributed to two labeled microtubes (500 ul each) and placed on ice for delivery to the clinic for injection into patient's metastatic lesions. Cells were injected based on CT scan information.
8. Preparation of adjuvants
[0047] Different adjuvants were included in the protocols: Commercially available (1) super lymphoid tissue extract (S-LTE, 0.5ml, Shukokai, Inc., Japan, Protocols I and II); (2) β-glucan (0.5ml-1.0 ml at 50 ug/ml in saline, Wako, Japan, Protocols II and III); or (3) keyhole limpet hemocyanin (KLH), 1 mg, Immucothel, Protocol IV,
prepared per manufacturer's recommendation; and (4) Activated Lymphocyte Medium (ALM); Protocols III, IV and V, prepared in our clinical laboratory from elutriated lymphocytes (Gambro BCT, Colorado, USA). To make ALM, lymphocytes were suspended at 1 x 106 cells/ml in 50 ml XVIVO 10 medium (Cambrex, Walkersville, MD) per T-75 cm2 flask and CD3-CD28 T cell expander beads (Dynal. Norway) (Levine, B.L. et al., J Immunol, 159:5921-30, 1997) were added at 1 cell to 1 bead ratio and incubated at 37°C, 5% CO2 for 2 days. The supematants were harvested by centrifugation at 300xg for 7 min and stored at 4°C for later use. All adjuvants were delivered intratumorally at the same time as delivery of DCs.
9. Chemotherapy
[0048] The type of chemotherapy was selected based on standard treatment for the particular cancer. Chemotherapy was administered intratumorally or systemically depending on the protocol. Twenty-one patients received Cyclophosphamide (CPM, 5-800 mg, Shinogi), five patients received Cisplatin (CDDP, 2.5-5.0 mg, Nihon Kayaku), one patient received Docetaxel (DTX, 55mg, Aventis), and one patient received Doxorubicin (ADM, 20mg, Kyowa Hakko). CDDP was administered systemically in combination with Fluorouracil (5-FU, 900 mg/day, Kyowa Hakko) in one patient with upper pharyngeal cancer.
10. Radiotherapy
[0049] Radiotherapy (20-50 Gy) was given to the two patients on Protocol V. One patient with metastatic upper pharyngeal cancer received 50 Gy and the other with recurrent metastatic esophageal cancer received 20 Gy. Radiotherapy was delivered to patients according to a defined protocol (Shimamura, H. et al., Eur Surg Res, 37:228-34, 2005). The radiation area of the tumor site was designated in advance and radiation was given at 2-2.5 Gy doses during a 3-4 week period. Radiotherapy was performed during the same period as chemotherapy. DCs were injected intratumorally seven days following the completion of radiotherapy and AT cells were injected intratumorally ten days following completion of radiotherapy or three days following DC injection in the applicable protocols.
11. Evaluation of responses
[0050] Carcinoembryonic antigen (CEA) levels elevated in cancer, such as cancer of the colon, rectum, stomach, breast, lung or pancreas, were used to monitor patient responses to treatment and disease recurrence. Tumor size of the injected and
irradiated sites, as well as metastatic sites, was evaluated prior to and 3-4 weeks following treatment using PET-CT imaging and Response Evaluation Criteria in Solid Tumors (RECIST). Baseline sums were assessed as the largest diameter in measurable lesions. The efficacy of treatment was assessed as complete response (CR, defined as complete disappearance of measurable lesions, with no new lesions developing and maintained for greater than 4 weeks), partial response (PR, defined as at least a 30% reduction in the size of injected tumors), stable disease (SD, defined as less than 30% reduction and less than 20% increase in size, with no new lesions developing) and progressive disease (PD, defined as 20% or greater increase of original measurements). Adverse effects were recorded using common WHO toxicity criteria.
12. Statistical measures
[0051] Tumor size data pre-and post treatment to gauge changes were compared using the Student's t test and paired t test. Statistical significance was determined at p<0.05. III. Results
1. Characterization of DCs and AT cells
[0052] Adherent PBMCs can be differentiated to DCs. Seven day cultured adherent cells from patients with a variety of cancers expressed costimulatory markers and low CD83 surface antigen, indicative of immature DCs (Table 3). Cell viability remained high at 85-95% following 7 days in culture, as well as following cryopreservation. Lymphocytes treated with anti-CD3 and ionomycin for activated T cell therapy expressed CD25 and CD4OL (Table 3). The viability of the stimulated cells ranged from 75-90% prior to and following cryopreservation.
Table 3
CD83+ 16 ± 16 CDl Ic+ 66 ± 22
CD25+ 87 ± 11
CD154" (CD40L) 31 ± 15
HLA-DR 79 ± 12
2. Toxicity
[0053] Blood and urine tests conducted during and following treatment showed no changes in total protein, glutamate oxaloacetic transaminase (GOT), glutamic pyruvic transaminase (GPT), lactate dehydrogenase (LDH), alkaline phosphatase, total bilirubin, blood urea nitrogen (BUN), creatinine, total cholesterol, triglycerides, blood sugar, hematuria or proteinuria.
[0054] All treatments were generally well-tolerated with adverse reactions limited to a few patients in the groups receiving AT cell therapy (Table 4). No local or systemic adverse reactions were observed immediately after injection or during the follow-up period in patients receiving DCs + adjuvant on Protocols I and II. In patients receiving AT cell therapy, fever (38°C) was observed in four patients on Protocol III just after injection and the two patients in Protocol V experienced injection site swelling, lymphadenopathy, and pain and fever.
Table 4. Adverse Reactions
3. Patient Response
[0055] Clinical efficacy was observed by comparing tumor size prior to therapy and 3-4 weeks following the first DC injection (Table 5).
Table 5.
Effectiveness of Treatment
DCs + adjuvant + DCs + adjuvant + AT Cells +
— chemo chemo chemo chemo + tumor rad tumor sys sys
CR = Complete Response; PR = Partial Response; SD = Stable Disease; PD = Progressive Disease ; chemo tumor = tumor injection of chemotherapy; chemo sys = systemic administration of chemotherapy; rad = tumor irradiation; a Responses limited to DC-injected site; b PET-CT data showed improvement in both DC-injected and metastatic sites
[0056] Seven of 37 patients (19%) responded to treatment with complete (one patient in Protocol V) or partial regression (six patients in Protocols I and II) in the tumor area which was observed for at least 3 months. Complete tumor regression was seen in a patient diagnosed with recurrence of upper pharyngeal cancer receiving DCs, AT cells and both chemotherapy and radiation (Protocol V, Figure 2) with efficacy at both treated and metastatic sites.
[0057] In 25 of 37 (67%) patients across all protocols, tumor size remained the same and did not change for at least 3 months. Serum tumor markers were followed in patients where indicated for a particular tumor and stabilized over this period of time. However, one patient with metastatic gastric adenocarcinoma showed a dramatic decline in CEA levels following injection of DCs and AT cells (Figure 3). The patient was diagnosed approximately 3 years prior to enrollment in our protocol and had undergone multiple rounds of chemotherapy and a subtotal gastrectomy. Despite these standard treatment approaches, CEA levels continued to rise and there was an increase in size of the periaortic lymph nodes. The patient received 800 mg of cyclophosphamide prior to injection of DCs followed by AT cells. Serum CEA levels showed a steady decline reaching a level of 6.7 at the latest examination. [0058] Progressive disease was observed in four patients receiving DCs alone or DCs with chemotherapy (Protocols I and II) and in one patient receiving DCs and AT cells with chemotherapy and radiation (Protocol V). In the latter, stable disease was observed for 1 month with progression at 3 months in untreated tumors. IV. Discussion
[0059] Anti-cancer treatments, including, tumor irradiation, chemotherapy and adoptive cellular therapy have shown effectiveness on their own. The primary purpose of this study was to determine the safety and efficacy of administering autologous immature DCs directly into tumors and then combining this approach with
other treatment modalities such as direct injection of a metastatic lesion with activated T cells, pretreatment with local chemotherapy or radiation to the injection site or systemic chemotherapy, in a variety of advanced stage cancer patients. This study showed that combining the unique properties of the different treatment modalities within single protocols significantly augmented anti-tumor responses. [0060] It is well-established that DCs serve as important antigen presenting cells for the induction of specific T cell immunity (Banchereau, J. et al., Nature 392: 245- 52; 1998) and, as such, have formed the basis of a number of clinical trials in a variety of cancers. Some trials have employed ex vivo generated DCs loaded with tumor- specific antigens, which can result in induction of anti-tumor immunity when reinfused into the host (Hsu, FJ. et al., Nat. Med., 2:52-58, 1996). However, in cancers where tumor-associated antigens are not well defined, as in this study, the whole tumor has been used in the form of apoptotic cells. Apoptotic cells effectively cross-prime T cell responses and induce potent immunity.
[0061] Ionizing radiation and chemotherapy is used to induce apoptosis. Tumor irradiation typically produces inflammation due to release of intracellular contents into the surrounding environment accompanied by, but not limited to, activation of cytokines, prostaglandins and heat shock proteins. Local delivery of chemotherapy creates a similar environment at the tumor site. Such strategies produce a milieu that facilitates antigen acquisition, processing, and maturation, as well as stimulate migration of DCs to draining lymph nodes where they interact with a broad range of potential effector cells.
[0062] Combining conformal radiotherapy and chemotherapy with DC intratumoral injection improves immune responsiveness shown both in human and murine models and from a practical standpoint, direct injection can ensure adequate quantities of antigen for loading onto DCs.
[0063] Because the primary goal of this study was to assess the safety and efficacy of different treatments using immature DCs as the base immunization, a group of patients was first injected with DCs directly into untreated tumors (Protocol I). No adverse reactions were observed using this method of injection and some patients actually showed partial responses at the tumor site (25%, 2/8), some had stable disease (50%, 4/8), while disease progressed in some patients (25%, 2/8). No adverse reactions were observed in the next group of patients, when local tumor chemotherapy
was added to enhance antigen uptake by DCs (Protocol II). The addition of local treatment actually seemed to slightly improve local partial tumor responses (40%, 4/10). Patients also developed stable (40%, 4/10) and progressive disease (20%, 2/10).
[0064] It has been suggested that tumor cells undergoing apoptosis may not induce immunity due to local secretion of immunosuppressive factors such as TGFO and ILlO and the lack of enough systemic functional DCs to reach the peritumoral region (Bodey, B. et al., Anticancer Res., 20: 2665-76, 2000). The tumor environment determines the state of maturation which can result in the induction of tolerance or immunity. Therefore, to complete DC activation at the injected site, other proinflammatory cytokines or immune-provoking substances may need to be combined with the immature DCs.
[0065] Combining DCs with other cell types, such as AT cells, therefore, is a promising therapy. DCs activate T cells and their interaction is important for the establishment of an effective immune response. Activated T cells could influence antigen presentation by DCs by a number of mechanisms. AT cells express surface molecules that physically interact with immature DCs and in addition produce cytokines and chemokines that influence the maturation and migration of DCs to regional lymph nodes where adaptive immune responses to acquired antigens are generated. As a consequence, a tumor specific immune response potentially is developed and long-term memory established.
[0066] There are different strategies in generating T cells for adoptive therapy which influence not only their antigen-specificity, tumor avidity and cellular phenotype, but also their behavior in vivo such as longevity, trafficking and antitumor efficacy. T cells have been expanded by a variety of methods including in vitro stimulation to elicit antigen-specific T cells from peripheral blood using cells engineered for antigen presentation (e.g., DCs pulsed with peptide or RNA transfected) or artificial antigen presenting cells. Harvesting infiltrating lymphocytes from tumor cells yield polyclonal T cell populations with broad reactivity to tumor. Re-infusing these cells after in vitro expansion has been used as an immunotherapeutic treatment modality. Another approach has been to activate and expand peripheral blood lymphocytes by triggering the T cell receptor and costimulatory molecules with antibodies and/or the use of cytokines to drive T cells.
[0067] In this study, AT cells were expanded from peripheral blood lymphocytes by anti-CD3-IL2 culture and ionomycin activation to upregulate CD4OL. Cultured AT cells were injected intratumorally, several days following DC injection, with the idea that antigen-specific T cells could be generated. Patients receiving AT cell therapy were pretreated with: I) local chemotherapy (Protocol III), 2) systemic chemotherapy (Protocol IV), or 3) systemic chemotherapy and local tumor irradiation (Protocol V).
[0068] When local tumor irradiation was added in the third AT cell protocol (Protocol V), transient fever, lymphadenopathy, pain in metastatic sites, and swelling in the injection site following AT cell injection appeared in two patients. These symptoms improved within 1 week and remarkably, in one patient with pharyngeal cancer, complete tumor regression of both treated and untreated sites was observed. Beginning at 3 weeks following treatment, except for the injection site, there was regression in all areas including the pharynx, larynx and bilateral cervical lymph node and by the nine-month follow up, tumors completely regressed including at the injection site. The second patient in this treatment group who had a very advanced stage of esophageal cancer seemed to respond initially but then developed progressive disease. It is not clear which part of the therapy contributed to the responses which could be due to strong inflammatory reactions, control or lack of immunosuppressive factors or a combination of these or other events. Fever was associated in the two groups who received both AT cells and local tumor treatment with either chemotherapy (Protocol III) or radiation (Protocol V), suggesting the release of inflammatory cytokines that are known to cause such reactions. These adverse reactions may, in fact, be required for an immune response to be generated to the tumor.
[0069] Chemotherapeutic agents were administered systemically or locally in an attempt to determine if these agents could be used safely and effectively with immunotherapeutic procedures. The doses of chemotherapy were not the amount generally considered optimal for treating the patients' malignancy but rather as support for developing an immune response to the cancer. Chemotherapy may induce apoptosis in the tumor cell augmenting antigen uptake. More importantly, these drugs may effect regulatory T cells. Regulatory cells generally defined as CD4+CD25+ have been found in most human solid tumors at elevated numbers with frequencies likely
correlated to overall survival (Beyer, M. et al., Blood 108: 804-11, 2006). Their elimination by direct targeting of CD25 on the cell surface or preferential destruction is known to result in the generation of tumor-specific and enhanced responses to immunotherapy. The use of low-dose cyclophosphamide, in particular, has been recognized to not only decrease the number of regulatory cells but to also exert immunostimulatory effects. No adverse events were seen when chemotherapy was given systemically prior to DC and AT cell injection. Although the objective of this study was safety and not necessarily therapeutic efficacy, any apparent benefit that was observed by the combination of these modalities must be viewed with the realization that each treatment (chemotherapy, radiation, immature DC and AT cell injection) may have had an effect on the tumor. Indeed, the two patients (head and neck cancer (Protocol V), gastric cancer (Protocol V)) had both failed standard radiation/chemotherapy, but showed substantial responses when receiving a combination of radiation and/or chemotherapy followed by intratumoral injection of DCs and AT cells.
[0070] Overall, this study demonstrated that all of the treatment protocols could be relatively well tolerated and that the combination of intratumoral injection of immature DCs and AT cells plus conventional therapy to enhance immunogenicity or override tolerance could be safely and effectively incorporated into single protocols. [0071] While the invention has been particularly shown and described with reference to preferred embodiments thereof, it will be understood by those skilled in the art that various alterations in form and detail may be made therein without departing from the spirit and scope of the invention, as defined by the appended claims.
Claims
1. A method of reducing the size of tumor cells in tumor tissue of a patient, comprising the steps of: collecting monocyte cells from a patient; culturing the monocyte cells with one or a plurality of factors to form immature dendritic cells from the monocyte cells; introducing the immature dendritic cells and an adjuvant into the tumor tissue of the patient; and introducing activated T cells into the tumor tissue of the patient.
2. The method according to claim 1 , wherein the introduction of the immature dendritic cells, adjuvant and activated T cells is effected by intratumoral injection.
3. The method according to claim 1, wherein said activated T cells are introduced subsequent to introducing the immature dendritic cells and the adjuvant into the patient, in order to generate antigen-specific T cells.
4. The method according to claim 1 , wherein said monocyte cells are cultured with GM-CSF and IL-4.
5. The method according to claim 1, wherein said adjuvant is selected from the group consisting of activated lymphocyte medium, super lymphoid tissue extract, β- glucan and keyhole limpet hemocyanin.
6. The method according to claim 5, wherein the activated lymphocyte medium is prepared by using CD3-CD28 beads.
7. The method according to claim 1, wherein activation of the activated T cells is accomplished by exposing T cells to anti-CD3 antibodies and an ionophore.
8. The method according to claim 7, wherein the ionophore is ionomycin.
9. The method according to claim 1, further comprising pretreating the patient with local chemotherapy prior to introducing the immature dendritic cells, adjuvant and activated T cells into the tumor tissue of the patient.
10. The method according to claim 1, further comprising pretreating the patient with systemic chemotherapy prior to introducing the immature dendritic cells, adjuvant and activated T cells into the tumor tissue of the patient.
11. The method according to claim 1 , further comprising pretreating the patient with systemic chemotherapy and local tumor irradiation prior to introducing the immature dendritic cells, adjuvant and activated T cells into the tumor tissue of the patient.
12. The method according to claim 1, wherein the patient is a human.
13. A cancer vaccine which when introduced into tumor tissue combines with an antigen for the reduction of the size of a tumor in a patient, said cancer vaccine comprising immature dendritic cells derived from monocyte cells collected from the patient, an adjuvant, antigens from the tumor in the patient, and activated T cells.
14. The cancer vaccine according to claim 13, wherein said vaccine is introduced into the tumor tissue of the patient by intratumoral injection.
15. The cancer vaccine according to claim 13, wherein said monocyte cells are cultured with GM-CSF and IL-4.
16. The cancer vaccine according to claim 13, wherein said adjuvant is selected from the group consisting of activated lymphocyte medium, super lymphoid tissue extract, β-glucan and keyhole limpet hemocyanin.
17. The cancer vaccine according to claim 16, wherein the activated lymphocyte medium is prepared by using CD3-CD28 beads.
18. The cancer vaccine according to claim 13, wherein activation of the activated T cells is effected by exposing T cells to anti-CD3 antibodies and an ionophore.
19. The cancer vaccine according to claim 18, wherein the ionophore is ionomycin.
20. The cancer vaccine according to claim 13, wherein said patient is a human.
Priority Applications (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP07871309A EP2091334A4 (en) | 2006-10-31 | 2007-10-31 | Dendritic cell tumor injection therapy and related vaccine |
JP2009535441A JP2010508364A (en) | 2006-10-31 | 2007-10-31 | Dendritic cell tumor injection therapy and related vaccines |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US85590506P | 2006-10-31 | 2006-10-31 | |
US60/855,905 | 2006-10-31 |
Publications (3)
Publication Number | Publication Date |
---|---|
WO2008063837A2 WO2008063837A2 (en) | 2008-05-29 |
WO2008063837A9 true WO2008063837A9 (en) | 2008-08-07 |
WO2008063837A3 WO2008063837A3 (en) | 2008-09-18 |
Family
ID=39430435
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2007/083161 WO2008063837A2 (en) | 2006-10-31 | 2007-10-31 | Dendritic cell tumor injection therapy and related vaccine |
Country Status (3)
Country | Link |
---|---|
EP (1) | EP2091334A4 (en) |
JP (1) | JP2010508364A (en) |
WO (1) | WO2008063837A2 (en) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20120128656A1 (en) | 2008-05-02 | 2012-05-24 | Immunovative Therapies, Ltd. | Vaccine compositions and methods |
SG11201510552WA (en) * | 2012-06-27 | 2016-01-28 | Hasumi Internat Res Foundation | Therapy and method for intratumorally introducing cytotoxic t lymphocyte and/or nkt cell with anti-tnf and/or anti-il-10 |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2002087627A1 (en) * | 2001-04-27 | 2002-11-07 | Xcyte Therapies, Inc. | Maturation of antigen-presenting cells using activated t cells |
KR20060023519A (en) * | 2003-02-21 | 2006-03-14 | 하스미 엘엘씨 (디비에이 슈코카이 인터내셔널) | Human lymphocyte vaccine adjuvant |
US20060216269A1 (en) * | 2004-09-17 | 2006-09-28 | Kenichiro Hasumi | Dendritic cell tumor injection (DCTI) therapy |
-
2007
- 2007-10-31 WO PCT/US2007/083161 patent/WO2008063837A2/en active Application Filing
- 2007-10-31 EP EP07871309A patent/EP2091334A4/en not_active Withdrawn
- 2007-10-31 JP JP2009535441A patent/JP2010508364A/en active Pending
Also Published As
Publication number | Publication date |
---|---|
WO2008063837A3 (en) | 2008-09-18 |
WO2008063837A2 (en) | 2008-05-29 |
EP2091334A2 (en) | 2009-08-26 |
EP2091334A4 (en) | 2010-02-03 |
JP2010508364A (en) | 2010-03-18 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US20220016164A1 (en) | Pharmaceutical composition for use in the treatment of pancreatic cancer | |
JP2005523277A (en) | Cancer treatment | |
EP2787005A1 (en) | Targeted cancer immune therapy | |
JP2005515781A (en) | Methods for inducing differentiation of monocytes into functional dendritic cells and immunotherapy compositions comprising such dendritic cells | |
AU2002324255B2 (en) | Process for the maturation of dentritic cells and a vaccine | |
EP3592841A1 (en) | Methods and compositions for treating cancers using antisense | |
Tjoa et al. | Dendritic cell-based immunotherapy for prostate cancer | |
JP2024019229A (en) | Activated dendritic cell compositions and methods for immunotherapy treatment for subjects with advanced cancer | |
EP1835931A2 (en) | Alpha thymosin peptides as cancer vaccine adjuvants | |
US20080160050A1 (en) | Dendritic cell tumor injection therapy and related vaccine | |
US20210353674A1 (en) | Pharmaceutical composition for use in the treatment of pancreatic cancer | |
Jouanneau et al. | Dendritic cells are essential for priming but inefficient for boosting antitumour immune response in an orthotopic murine glioma model | |
JP2004531496A (en) | Use of Gram-negative bacterial membrane fraction to induce dendritic cell maturation | |
WO2008063837A2 (en) | Dendritic cell tumor injection therapy and related vaccine | |
Mann et al. | Combining conventional therapies with intratumoral injection of autologous dendritic cells and activated T cells to treat patients with advanced cancers | |
JP2002502880A (en) | Hapten-modified tumor cell membranes and uses thereof | |
Schwaab et al. | Tumor‐related immunity in prostate cancer patients treated with human recombinant granulocyte monocyte‐colony stimulating factor (GM‐CSF) | |
US20170246207A1 (en) | Antigen specific mrna cellular cancer vaccines | |
RU2309753C1 (en) | Combined cell transplant based on lymphokine-activated killers and dendrite cells, method for production thereof and method for treatment and prophylaxis of malignant, infective diseases and immunodeficient conditions | |
Lozano et al. | Technical challenges in the manufacture of dendritic cell cancer therapies | |
Volk et al. | Tumor cell-based vaccination in renal cell carcinoma: rationale, approaches, and recent clinical development | |
US20240024443A1 (en) | Augmentation of survivin modified mrna vaccine efficacy using dendritic cells | |
JP5084012B2 (en) | Idiotype antigen carrier and idiotype vaccine using the same | |
WO2001062092A1 (en) | Formulations and methods for using the same to elicit an immune response | |
Xu et al. | In vitro analysis of the antileukemic effect of tumor necrosis factor‐α gene therapy with myeloid progenitor cells: the role of dendritic cells 1 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 07871309 Country of ref document: EP Kind code of ref document: A2 |
|
ENP | Entry into the national phase |
Ref document number: 2009535441 Country of ref document: JP Kind code of ref document: A |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2007871309 Country of ref document: EP |